Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Wirth

Showing results (151-160 of 165) with videos related to

Pageof 17
Sort By:
Hepatology (Baltimore, Md.)|April 25, 2018
Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE StudyStefan Wirth, Hongfei Zhang, Winita Hardikar, et al.
The Lancet. Gastroenterology & Hepatology|April 16, 2019
Hepatitis B virus infection in children and adolescentsGiuseppe Indolfi, Philippa Easterbrook, Geoffrey Dusheiko, et al.
The Lancet. Gastroenterology & Hepatology|April 16, 2019
Hepatitis C virus infection in children and adolescentsGiuseppe Indolfi, Philippa Easterbrook, Geoffrey Dusheiko, et al.
Hepatology (Baltimore, Md.)|May 26, 2017
Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infectionStefan Wirth, Philip Rosenthal, Regino P Gonzalez-Peralta, et al.
The American Journal of Clinical Nutrition|March 24, 2023
Uncovering the gastrointestinal passage, intestinal epithelial cellular uptake, and AGO2 loading of milk miRNAs in neonates using xenomiRs as tracersPatrick Philipp Weil, Susanna Reincke, Christian Alexander Hirsch, et al.
Hepatology Communications|November 10, 2018
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4Daniel H Leung, Stefan Wirth, Betty B Yao, et al.
Hepatology Communications|February 15, 2023
Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling studyRegino P Gonzalez-Peralta, Stefan Wirth, Robert H Squires, et al.
Frontiers in Allergy|April 7, 2022
The Rhinobiome of Exacerbated Wheezers and Asthmatics: Insights From a German Pediatric Exacerbation NetworkMalik Aydin, Cornelius Weisser, Olivier Rué, et al.
European Radiology|November 5, 2020
The practice of emergency radiology throughout Europe: a survey from the European Society of Emergency Radiology on volume, staffing, equipment, and schedulingMariano Scaglione, Raffaella Basilico, Andrea Delli Pizzi, et al.
Hepatology (Baltimore, Md.)|June 22, 2019
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 InfectionPhilip Rosenthal, Kathleen B Schwarz, Regino P Gonzalez-Peralta, et al.
Pageof 17

Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
Hepatology (Baltimore, Md.)|April 25, 2018
Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE StudyStefan Wirth, Hongfei Zhang, Winita Hardikar, et al.
The Lancet. Gastroenterology & Hepatology|April 16, 2019
Hepatitis B virus infection in children and adolescentsGiuseppe Indolfi, Philippa Easterbrook, Geoffrey Dusheiko, et al.
The Lancet. Gastroenterology & Hepatology|April 16, 2019
Hepatitis C virus infection in children and adolescentsGiuseppe Indolfi, Philippa Easterbrook, Geoffrey Dusheiko, et al.
Hepatology (Baltimore, Md.)|May 26, 2017
Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infectionStefan Wirth, Philip Rosenthal, Regino P Gonzalez-Peralta, et al.
The American Journal of Clinical Nutrition|March 24, 2023
Uncovering the gastrointestinal passage, intestinal epithelial cellular uptake, and AGO2 loading of milk miRNAs in neonates using xenomiRs as tracersPatrick Philipp Weil, Susanna Reincke, Christian Alexander Hirsch, et al.
Hepatology Communications|November 10, 2018
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4Daniel H Leung, Stefan Wirth, Betty B Yao, et al.
Hepatology Communications|February 15, 2023
Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling studyRegino P Gonzalez-Peralta, Stefan Wirth, Robert H Squires, et al.
Frontiers in Allergy|April 7, 2022
The Rhinobiome of Exacerbated Wheezers and Asthmatics: Insights From a German Pediatric Exacerbation NetworkMalik Aydin, Cornelius Weisser, Olivier Rué, et al.
European Radiology|November 5, 2020
The practice of emergency radiology throughout Europe: a survey from the European Society of Emergency Radiology on volume, staffing, equipment, and schedulingMariano Scaglione, Raffaella Basilico, Andrea Delli Pizzi, et al.
Hepatology (Baltimore, Md.)|June 22, 2019
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 InfectionPhilip Rosenthal, Kathleen B Schwarz, Regino P Gonzalez-Peralta, et al.
Pageof 17